CTX 2026
Alternative Names: CTX-2026Latest Information Update: 28 Sep 2024
At a glance
- Originator Compass Therapeutics
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Butyrophilin inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Ovarian cancer
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for preclinical development in Ovarian-cancer(Monotherapy) in USA (Parenteral)
- 13 May 2024 Compass Therapeutics has patents pending for CD277 targeting antibody in USA and foreign jurisdictions
- 28 Feb 2022 No recent reports of development identified for research development in Cancer(Combination therapy) in USA (Parenteral)